Catheter Ablation of Ventricular Tachycardia in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: A Sequential Approach.
Action Potentials
Adult
Arrhythmogenic Right Ventricular Dysplasia
/ complications
Catheter Ablation
/ adverse effects
Disease-Free Survival
Endocardium
/ physiopathology
Female
Heart Rate
Humans
Male
Middle Aged
Pericardium
/ physiopathology
Recurrence
Retrospective Studies
Risk Factors
Tachycardia, Ventricular
/ diagnosis
Time Factors
arrhythmogenic right ventricular dysplasia/cardiomyopathy
catheter ablation
epicardial ablation
ventricular tachycardia
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
05 03 2019
05 03 2019
Historique:
entrez:
1
3
2019
pubmed:
1
3
2019
medline:
15
7
2020
Statut:
ppublish
Résumé
Background It has been suggested that endocardial and epicardial ablation of ventricular tachycardia ( VT ) improves outcome in arrhythmogenic right ventricular cardiomyopathy/dysplasia. We investigated our sequential approach for VT ablation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia in a single center. Methods and Results We included 47 patients (44±16 years) with definite (81%) or borderline (19%) arrhythmogenic right ventricular cardiomyopathy/dysplasia between 1998 and 2016. Our ablation strategy was to target the endocardial substrate. Epicardial ablation was performed in case of acute ablation failure or lack of an endocardial substrate. Single and multiple procedural 1- and 5-year outcome data for the first occurrence of the study end points (sustained VT /ventricular fibrillation, heart transplant, and death after the index procedure, and sustained VT /ventricular fibrillation for multiple procedures) are reported. Eighty-one radiofrequency ablation procedures were performed (mean 1.7 per patient, range 1-4). Forty-five (56%) ablation procedures were performed via an endocardial, 11 (13%) via an epicardial, and 25 (31%) via a combined endo- and epicardial approach. Complete acute success was achieved in 65 (80%) procedures, and partial success in 13 (16%). After a median follow-up of 50.8 (interquartile range, [18.6; 99.2]) months after the index procedure, 17 (36%) patients were free from the primary end point. After multiple procedures, freedom from sustained VT /ventricular fibrillation was 63% (95% CI , 52-75) at 1 year, and 45% (95% CI , 34-61) at 5 years, with 36% of patients receiving only endocardial radiofrequency ablation. A trend (log rank P=0.058) towards an improved outcome using a combined endo-/epicardial approach was observed after multiple procedures. Conclusion Endocardial ablation can be effective in a considerable number of arrhythmogenic right ventricular cardiomyopathy/dysplasia patients with VT , potentially obviating the need for an epicardial approach.
Identifiants
pubmed: 30813830
doi: 10.1161/JAHA.118.010365
pmc: PMC6474920
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e010365Références
J Am Heart Assoc. 2019 Mar 5;8(5):e010365
pubmed: 30813830
Herz. 2000 May;25(3):210-5
pubmed: 10904840
J Am Coll Cardiol. 2007 Jul 31;50(5):432-40
pubmed: 17662396
J Cardiovasc Electrophysiol. 2013 Oct;24(10):1157-62
pubmed: 23718822
Heart Rhythm. 2015 Apr;12(4):716-25
pubmed: 25530221
J Interv Card Electrophysiol. 2017 Mar;48(2):193-199
pubmed: 27900527
Circulation. 2004 Oct 19;110(16):2293-8
pubmed: 15477406
J Cardiovasc Electrophysiol. 2013 Dec;24(12):1311-20
pubmed: 23889974
Circulation. 2003 Dec 23;108(25):3084-91
pubmed: 14638546
Circ Arrhythm Electrophysiol. 2012 Jun 1;5(3):499-505
pubmed: 22492430
Circ Arrhythm Electrophysiol. 2013 Jun;6(3):562-8
pubmed: 23673907
Europace. 2017 Apr 1;19(4):607-616
pubmed: 28431051
Circulation. 2005 Jun 21;111(24):3209-16
pubmed: 15956125
J Am Coll Cardiol. 2014 Apr 15;63(14):1416-26
pubmed: 24486269
Circulation. 2010 Apr 6;121(13):1533-41
pubmed: 20172911
Eur Heart J. 2015 Dec 7;36(46):3227-37
pubmed: 26216920
Circ Cardiovasc Imaging. 2014 Mar;7(2):230-9
pubmed: 24515411
Circ Arrhythm Electrophysiol. 2012 Feb;5(1):111-21
pubmed: 22205683
Heart Rhythm. 2011 Jan;8(1):76-83
pubmed: 20933099
Circ Arrhythm Electrophysiol. 2015 Dec;8(6):1413-21
pubmed: 26546346
JACC Clin Electrophysiol. 2018 Feb;4(2):243-253
pubmed: 29749945
Circulation. 1998 Apr 28;97(16):1571-80
pubmed: 9593562
J Am Coll Cardiol. 2010 Oct 12;56(16):1320-7
pubmed: 20888522
Circ Arrhythm Electrophysiol. 2013 Feb;6(1):144-50
pubmed: 23392586
Heart Rhythm. 2010 Dec;7(12):1746-52
pubmed: 20709191
Lancet. 2009 Apr 11;373(9671):1289-300
pubmed: 19362677
Circulation. 2009 Aug 4;120(5):366-75
pubmed: 19620503
Circ Arrhythm Electrophysiol. 2015 Feb;8(1):87-93
pubmed: 25527825
Circ Cardiovasc Genet. 2012 Feb 1;5(1):18-24
pubmed: 22238189
J Forensic Leg Med. 2015 May;32:10-5
pubmed: 25882142
J Am Coll Cardiol. 2010 May 25;55(21):2366-72
pubmed: 20488308
J Cardiovasc Electrophysiol. 2016 Jan;27(1):80-7
pubmed: 26471955
Circulation. 2013 Sep 17;128(12):1381-6
pubmed: 24043146
Circulation. 2010 Sep 21;122(12):1144-52
pubmed: 20823389
BMC Cardiovasc Disord. 2015 Jan 19;15:4
pubmed: 25599583
J Am Coll Cardiol. 1995 Oct;26(4):1080-9
pubmed: 7560602
Circ Arrhythm Electrophysiol. 2011 Aug;4(4):478-85
pubmed: 21665983